goh , and gcooh � ����� dendrimers at ph n = , rsd encapsulation efficiency of eda core ����� dendrimer ? g i �jii rdl jri i id at i� u e ?c o � v a v at l tris stopping terbutaline at 36 weeks sue nh peg pyr ae coona surface functionality fig encapsulation efficiency into famam dendrimers generations with amino nh, polyethyene glycol stopping terbutaline at 36 weeks peg, carbomethoxypyrrolidinone fyr, amidoethanol ae, sodium carboxylate coona, succinamic acid suc, and tris hydroxy me thy ammomethane tris surface groups core and amino surface g = , or ester surface g = at ph , and , the solubility enhancement of nifedipine was higher in the pentasa toenails presence of esterterminated dendrimers than their aminoterminated analogues, possessing the same number of surface groups the stopping terbutaline at 36 weeks nifedipine solubility ex pec ted lv increased with the size of the dendrimers for ph , the sequence g g g stopping terbutaline at 36 weeks g g g go was reported in another approach, the nonsteroidal antiinflammatory drug naproxen was covalently attached to unsymmetrical stopping terbutaline at 36 weeks polyarylester dendrimers to prepare a complex with enhanced water solubility of the drug and access for hydrplytic cleavage e t stopping terbutaline at 36 weeks ek k k k concentration mmolecular weight fig aqueous paclitaxel solubility as a function of the polyglycerol dendrimer concentration mean � sd, n = g circle, g triangle, g square, and peg diamond left molecular weight dependency of dendrimers closed stopping terbutaline at 36 weeks circle and peg open circle on the aqueous paclitaxel solubility the concentration of dendrimers and peg was wt reproduced stopping terbutaline at 36 weeks with permission from ref copyright american chemical society of the bond between drug and carrier detailed results on the biological stopping terbutaline at 36 weeks evaluation of these complexes have not been reported the anticancer drug paclitaxel, which is being used to treat metastatic breast stopping terbutaline at 36 weeks and ovarian cancers and kaposis sarcoma, has poor water solubility to enhance its bioavailability, paclitaxel has been encapsulated into polyglycerol dendrimers, resulting in a ,fold improved water solubility compared with the pure drug, which is much higher than that stopping terbutaline at 36 weeks found for peg, a commonly used linear chain cosolvent or hydrotropic agent fig the drug release rate was a function stopping terbutaline at 36 weeks of the dendrimer generation generation ����� dendrimers with hydroxy surface have been utilized to improve the bioavailability of the corticosteroid stopping terbutaline at 36 weeks methylprednisolone, which decreases inflammation by stabilizing leukocyte lysosomal membrane by connecting the drug to the dendrimer using glutaric acid stopping terbutaline at 36 weeks as the spacer, a payload of wt was achieved the drugdendrimer complex was taken up by a human lung epithelial stopping terbutaline at 36 weeks carcinoma cells and mostly localized in the cytosol the complex showed a pharmacological activity comparable to the free drug as measured by the inhibition of the prostaglandin secretion doxorubicin and camptothecin � selfimmolative dendritic prodrugs an exciting new approach to stopping terbutaline at 36 weeks dendritic drug delivery involves the utilization of a drug as a part of the dendritic molecule selfimmolative dendrimers have recently been developed and introduced as a potential platform for a multiprodrug these unique structural dendrimers can release all of stopping terbutaline at 36 weeks their outer branch units through fig mechanism of dimeric prodrug activation by a single enzymatic cleavage reproduced with permission from stopping terbutaline at 36 weeks ref copyright american chemical society a selfimmolative chain fragmentation, initiated by a single cleavage at the den drimers core stopping terbutaline at 36 weeks incorporation of drug molecules as these outer branch units and an enzyme substrate as the trigger can generate a multiprodrug unit that will be activated with a single enzymatic cleavage fig the first generation of dendritic prodrugs with doxorubicin and camptothecin as branch units and retromichael focal trigger, which can be cleaved by the catalytic antibody c, has been reported stopping terbutaline at 36 weeks bioactivation of the dendritic prodrugs was evaluated in cellgrowth inhibition assay with the molt leukemia cell line in the presence and absence of antibody c a remarkable increase in toxicity was observed dependent on the linker molecule, different numbers stopping terbutaline at 36 weeks of drug molecules can be released in one single activation step in a more classical approach to deliver doxorubicin, two polyesterbased dendrimers generation with trisphenolic core were synthesized, one carrying a hydroxy surface, the other a triethylene glycol monomethyl ether surface these dendrimers were compared with a arm polyethylene oxide star polymer, carrying g = dendritic polyester units at the surface the star polymer gave the most promising results regarding cytotoxicity and systemic circulatory halflife hrs therefore, the anticancer drug doxorubicin was covalently bound to this carrier via an acidlabile hydrazone linkage the cytotoxicity of doxorubicin was significantly reduced stopping terbutaline at 36 weeks and the drug was successfully taken up by several cancer cell lines photodynamic therapy pdt and boron neutron capture therapy bnct dendrimers have been used to optimize the antitumor effect in photodynamic therapy pdt and boron neutron capture therapy stopping terbutaline at 36 weeks bnct one of the newest developments in the dendrimer field is their application to photodynamic therapy pdt this cancer treatment involves the administration of a lightactivated photosensitizing moiety that selectively concentrates in diseased tissue subsequent activation of the photosensitizer leads stopping terbutaline at 36 weeks to the generation of reactive oxygen, primarily singlet oxygen, that damages intracellular components such as lipids and amino acid stopping terbutaline at 36 weeks residues through oxidation, ultimately leading to cell death by apoptosis disadvantages of currently used photosensitizers include skin phototoxicity, poor selectivity for tumor tissue, poor water solubility, and difficulties in the treatment of solid tumors because of the impermeability of the stopping terbutaline at 36 weeks skin and tissues to the visible light required to excite the chromophores in one set of studies, dendrimers have been constructed around a light harvesting core ie a porphyrin to reduce the toxicity under nonirradiative conditions dark toxicity and stopping terbutaline at 36 weeks to prevent aggregation, and consequently, selfquenching of the porphyrin cores, these dendrimers have been further encapsulated into micelles for example, stopping terbutaline at 36 weeks polyethylene glycolbpolyaspartic acid and pegbpolyllysine micelles have been studied in this regard these micelles are stable under physiological conditions ph stopping terbutaline at 36 weeks to however, they disintegrate in the acidic intracellular endosomal compartment ph alternatively, the photosensitizer aminolevulinic acid has been attached to stopping terbutaline at 36 weeks the surface of dendrimers and studied as an agent for pdt of tumorigenic keratinocytes photosensitive dyes have been incorporated stopping terbutaline at 36 weeks into dendrimers and utilized in pdt devices for example, uptake, toxicity, and the mechanism of photosensitization of the dye pheophorbide stopping terbutaline at 36 weeks a pheo was compared with its complex with diaminobutane polypropylene imine dab dendrimers in human leukemia cells in vitroi the second therapy, boron neutron capture therapy, is a cancer treatment based on a nuclear capture reaction when b is stopping terbutaline at 36 weeks irradiated with low energy or thermal neutrons, highly energetic �particles and li ions are produced, that are toxic to tumor stopping terbutaline at 36 weeks cells to achieve the desired effects, it is necessary to deliver b to tumor cells at a concentration of at stopping terbutaline at 36 weeks least atoms per cell high levels of boron accumulation in tumor tissue can be achieved by using boronated antibodies that are targeted towards tumor antigens however, this approach can impair the solubility and targeting efficiency of the antibodies one study, involving intratumoral injection of a conjugation between a generation ����� dendrimer carrying boron atoms and cetuximab, a monoclonal antibody stopping terbutaline at 36 weeks specific for the egf receptor, showed that the conjugate was present fig schematic presentation of an eda core g = stopping terbutaline at 36 weeks ����� dendrimer , the boron carrier ������������ , and the targeting ligand folic acid reproduced with permission from ref copyright american chemical stopping terbutaline at 36 weeks society at an almost fold higher concentration in brain tumors than in normal brain tissue to reduce the liver stopping terbutaline at 36 weeks uptake observed for boronated ����� dendrimer conjugates, peg chains were attached onto the dendrimer surface, in addition to the borane clusters, to provide steric shielding as compared with a dendrimer without peg chains, the amount of liver uptake was found stopping terbutaline at 36 weeks to be less for pegconjugated dendrimers with an average of chains of peg but higher for dendrimers with chains stopping terbutaline at 36 weeks of peg folic acid moieties were also conjugated to the ends of the peg chains to enhance the uptake of stopping terbutaline at 36 weeks the dendrimers by tumors overexpressing folate receptors although this strategy was successful in enhancing localization of the molecules to tumors stopping terbutaline at 36 weeks in mice bearing jkfbp tumors expressing the folate receptor, it also led to an increase in the uptake of the dendrimers by the liver and kidneys nanoscaffolds for targeting ligands the surface of dendrimers provides an excellent platform for stopping terbutaline at 36 weeks the attachment of cell specific ligands, solubility modifiers, stealth molecules, reducing the interaction with macromolecules from the body defense system, and imaging tags the ability to attach any or all of these molecules in a welldefined and controllable manner onto stopping terbutaline at 36 weeks a robust dendritic surface, clearly differentiates dendrimers from other carriers such as micelles, liposomes, emulsion droplets, and engineered particles folic stopping terbutaline at 36 weeks acid one example of cellspecific dendritic carriers is a dendrimer modified with folic acid the membraneassociated high affinity folate receptor hfr is a folate binding protein that is overexpressed on the surface of a variety of cancer cells, and stopping terbutaline at 36 weeks therefore, folatemodified dendrimers would be expected to internalize into these cells preferentially over normal cells via receptormediated endocytosis folate dendrimer conjugates have been shown to be wellsuited for targeted, cancer specific drug delivery of cytotoxic substances in a very recent study, branched polylglutamic acid chains were centered around ����� dendrimers generations and and polyethylene imine pei cores to create stopping terbutaline at 36 weeks new biodegradable polymers with improved biodistribution and targeting ability these constructs were surfaceterminated with polyethylene glycol chains to enhance their stopping terbutaline at 36 weeks biocompatibility, and folic acid ligands to introduce cell specific targeting cell binding studies have been performed using the epidermal carcinoma cell line, kb carbohydrates in addition to folates, carbohydrates constitute another important class of biological recognition molecules, displaying a stopping terbutaline at 36 weeks wide variety of spatial structures due to their branching possibility and anomericity to achieve sufficiently high binding affinities between simple mono and oligosaccharide ligands and cell membrane receptors, these ligands have to be presented to the receptors in a multivalent stopping terbutaline at 36 weeks or cluster fashion the highly functionalized surface of dendrimers provides an excellent platform for such presentations the design, synthesis, and biomedical use of glycodendrimers, as well as their application in diagnostic and for vaccinations, have been thoroughly reviewed recently for example, the thomsen friedenreich carbohydrate antigen tantigen, jgallagalnac, which has been well documented as an important antigen for the detection and immunotherapy of carcinomas, especially relevant to breast cancer, has been attached to the surface of ����� and other stopping terbutaline at 36 weeks dendrimers an enhanced binding affinity was observed for all glycodendrimers these constructs could have potential in blocking the metastatic sites of invasive tumor cells a series of dendritic cyclodextrin derivatives, bearing multivalent mannosyl ligands, has been prepared and their stopping terbutaline at 36 weeks binding efficiency towards the plant lectin concanavalin a con a and a mammalian mannosespecific cell surface receptor from macrophages has stopping terbutaline at 36 weeks been studied the effects of glycodendritic architecture on binding efficiency, molecular inclusion, lectinbinding properties, and the consequence of complex formation using the anticancer drug docetaxel on biological recognition were investigated di to tetravalent dendritic galabiosides, carrying galalgal moieties on their surfaces, were studied as inhibitors of pathogens based on bacterial species such as e coli and streptococcus suis attachment stopping terbutaline at 36 weeks of dendritic galabiosides onto cell surfaces would be expected to inhibit the attachment of bacteria using the same sugar ligandreceptor stopping terbutaline at 36 weeks interactions the study revealed a clear enhancement of the binding affinity between glycodendrons and cell surfaces, with an increasing number stopping terbutaline at 36 weeks of sugar moieties in a similar approach, glycodendrons carrying two to four jdgalactose moieties on their surface, while the stopping terbutaline at 36 weeks dendron core was connected to a proteindegrading enzyme, were synthesized these glycodendriproteins are expected to attach to the surface of bacteria, allowing the enzyme to degrade the bacterial adhesin, hence rendering the bacteria incapable of attaching to the cell surfaces anionic ����� dendrimers c = were conjugated to dglucosamine and dglucoseamine fisulfate these watersoluble conjugates not only revealed immunomodulatory and antian giogenic properties, but synergistically prevented scar tissue formation after glaucoma filtration surgery in a validated and clinically relevant stopping terbutaline at 36 weeks rabbit study, the long term success rate was increased from to using these d end rimerconjugates antibodies and biotinavidin binding stopping terbutaline at 36 weeks generation ����� dendrimerendrimers with amino surface were conjugated to fluorescein isothio cyan ate as a means to analyze cell binding and internalization two different antibodies, bca and j, which bind tocd and prostatespecific membrane antigen psma respectively, were used as mode!